TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04085185
Drug: IBI110
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI110 will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
Study: NCT00485862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02979704
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks
Study: NCT00909168
Drug: FLAIMy - Fluda, Ida, Ara-C, Mylotarg
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5~ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5~IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5~GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6
Study: NCT04264208
Drug: 68-Ga RM2.
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radiopharmaceutical
Study: NCT04264208
Drug: 68-Ga PSMA11
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radiopharmaceutical
Study: NCT03456466
Drug: TQB2303
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375mg/m2 ，iv
Study: NCT00652444
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
Study: NCT02135354
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * From day 1 up to and including day 3: 500 mg azithromycin PO once a day~* From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
Study: NCT02135354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * From day 1 up to and including day 3: 500 mg placebo PO once a day~* From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
Study: NCT03403569
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.
Study: NCT00652444
Drug: Placebo (Unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching ezetimibe placebo
Study: NCT04157010
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01219543
Drug: AZD1480 BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Dose, Capsule, BID Dosing
Study: NCT01255215
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)
Study: NCT01705938
Drug: SP-333
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02806440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT02027025
Drug: SPARC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02078908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 2 hour infusion of sodium chloride, 25 ml/hour
Study: NCT03427853
Drug: LY06006
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY06006 18mg, 60mg, 120mg subcutaneous injection
Study: NCT00003288
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04467840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
Study: NCT03427853
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection
Study: NCT01542450
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
Study: NCT00567034
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose placebo, 1 capsule every day for 12 weeks
Study: NCT02713178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline.
Study: NCT02557399
Drug: Duac® fixed dose combination gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
Study: NCT02557399
Drug: ADA 0.1% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADA 0.1% gel containing 0.1% of adapalene.
Study: NCT02557399
Drug: CLDM 1% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
Study: NCT01038622
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day placebo treatment
Study: NCT02071095
Drug: Arm B: Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
Study: NCT03748992
Drug: gNO
Normalized name: MAGNOLOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment.~Participants will be treated for 3 weeks (5 days per week), Monday through Friday, and followed monthly for 3 months.~The treatment period includes a physical exam, vital signs, blood tests, echocardiogram, spirometry test, sputum sample, questionnaires, and the inhalation gas treatment. During the inhalation gas treatment, participants will wear a face mask (similar to an oxygen mask) and will be given nitric oxide gas through the participants nose for three treatments with fifty minutes each time. They will then be followed up monthly during the Follow-up period with tests that include a physical exam and questionnaires.
Study: NCT04190355
Drug: 5.25% NaOCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.25% NaOCl solution
Study: NCT04554589
Drug: Glycopyrrolate 0.2 MG
Normalized name: glycopyrrolate 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: injections
Study: NCT04554589
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT02151617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Study: NCT02151617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily dosing for 14 days
Study: NCT02151617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
Study: NCT02151617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, once daily, 14 days
Study: NCT00871156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00333567
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03779451
Drug: 17-OHPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery.
Study: NCT04036721
Drug: Prolonged glucocorticosteroid (prednisone) regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.
Study: NCT04036721
Drug: Short glucocorticosteroid (prednisone) regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
Study: NCT03163407
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
Study: NCT04030598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching solution administered SC
Study: NCT01283100
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg once every 24 hours for 7 days
Study: NCT01283100
Drug: GSK2248761
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg once every 24 hours for 7 days
Study: NCT01921010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Description
Study: NCT00284921
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00606307
Drug: ITF2357
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration.
Study: NCT02439034
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen\* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
Study: NCT02563899
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.
Study: NCT00406679
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: equivalent volume IV 0.9% sodium chloride (equivalent volume)
Study: NCT03172598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT03049878
Drug: Paracetamol Codeine
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: preoperative administration
Study: NCT03049878
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: preoperative administration
Study: NCT01289886
Drug: BR-A-657
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20, 60, 120, 240, 360, 480mg or placebo tablet
Study: NCT02570347
Drug: Co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
Study: NCT00969709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules, oral administration, once daily for 8 weeks.
Study: NCT02956785
Drug: 10 mg Dinoprostone; CTS, UK
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956785
Drug: 3 mg Dinoprostone vaginal tablet; Pfizer, UK
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956785
Drug: Aquacryl hydrogel rod; HPSRx Enterprises, USA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00922636
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken in tablet form QD po.
Study: NCT03107338
Drug: DEXKETOPROFEN TROMETAMOL
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery
Study: NCT00605215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Study: NCT00605215
Drug: Avonex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avonex® will be administered per dose and schedule specified in the arm description.
Study: NCT00922636
Drug: Placebo (tablet)
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
Study: NCT00922636
Drug: Placebo (capsule)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
Study: NCT00023296
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03127592
Drug: Fixed Dose Combination
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg
Study: NCT03127592
Drug: Etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drug
Study: NCT03918499
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00603304
Drug: Placebo - first 24 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
Study: NCT00603304
Drug: Placebo - weeks 48 - 72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
Study: NCT01561937
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
Study: NCT01019161
Drug: AZD1152
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg Lyophile, 5mL Diluent IV infusion
Study: NCT01019161
Drug: C14 AZD1152
Normalized name: C14-22 alcohols
Approvals — FDA: no, EMA: no, PMDA: no
Description: radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
Study: NCT00266227
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00266227
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral or parenteral repeating dose
Study: NCT00649480
Drug: COLAZAL® Capsules 750 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x750mg, single dose fed
Study: NCT02874066
Drug: PTV/r/OBV/DSV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viekirax/Exviera for 12 weeks
Study: NCT03374345
Drug: Sipjeondaebo-tang Granule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study: NCT03374345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study: NCT01850446
Drug: Ergoferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and Efficacy
Study: NCT01056692
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules twice daily for 15 days
Study: NCT01056692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules twice daily for 15 days
Study: NCT03837210
Drug: Pylorin
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly Herbal formulation
Study: NCT01595373
Drug: Acyl ghrelin
Normalized name: gellan gum (low acyl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
Study: NCT01595373
Drug: Placebo (Ringer acetate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer acetate 2 microliter/min for 300 minutes
Study: NCT01127100
Drug: transdermal fentanyl matrix, gabapentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.~Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained.
Study: NCT02308501
Drug: Lastacaft ®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02308501
Drug: Tears Naturale ® (Placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04072042
Drug: Apatinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive Apatinib 250mg tablet by mouth, bid.
Study: NCT02074202
Drug: 18F- fluorocholine
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
Study: NCT02074202
Drug: 18F- fluorodeoxyglucose
Normalized name: fluorodeoxyglucose F18
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
Study: NCT01455870
Drug: ITCA 650 60 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: exenatide in DUROS
Study: NCT02169440
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 25 mg
Study: NCT03927573
Drug: GEM3PSCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles
Study: NCT01164644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take twelve pills by mouth three times a day over four days.
Study: NCT00619827
Drug: 300 IR grass pollen allergen extract tablet
Normalized name: orchard grass pollen extract 300 IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IR grass pollen allergen extract tablet once daily during four months
Study: NCT00619827
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily during four months
Study: NCT00524927
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00621777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks.
Study: NCT03485443
Drug: %0.9 NaCl 10ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration
Study: NCT03485443
Drug: %0.9 NaCl 20ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration
Study: NCT00194129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.
Study: NCT00112827
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01165307
Drug: Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
Study: NCT00353522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po daily for 24 weeks
Study: NCT01165307
Drug: Naproxen sodium pills
Normalized name: naproxen sodium Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
Study: NCT03234036
Drug: GSK2838232 100 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
Study: NCT03234036
Drug: GSK2838232 50 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
Study: NCT03234036
Drug: Placebo for GSK2838232 tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
Study: NCT01126099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules twice daily for 12 weeks
Study: NCT05014711
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before infusion, remifentanil is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.